ClinicalTrials.gg
Not yet recruitingNCT07006194Updated Jun 5, 2025

Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)

An interventional study of Nicotinamide Tablet in Glaucoma, sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara. Not yet recruiting at 3 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Planned enrollment
4th of 39
360 · median 64
Started
2025
with 3 others
No phase
17 of 53
1 open now
Registered
48th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 4th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 with no phase, and was the 48th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

Background Glaucoma is a multifactorial, chronic, and progressive eye disease characterized by the irreversible loss of retinal ganglion cells (RGCs). It is the second leading cause of blindness globally, with approximately 76 million patients affected in 2020, a number expected to rise to 120 million in the coming decades, especially in Africa and Asia. Elevated intraocular pressure (IOP) is a significant risk factor for glaucoma, and its reduction remains the only scientifically proven approach to slowing visual function decline. However, many glaucoma patients continue to experience visual loss even with IOP values within the normal range, due to the disease's multifactorial nature. Besides IOP reduction, there is a need for direct neuroprotection to address other factors causing RGC damage.

Mitochondrial dysfunction has emerged as a critical early factor in RGC damage, making glaucoma, at least in part, resemble a mitochondrial disease. Mitochondria play a key role in cellular functions such as energy production, redox metabolism, and maintaining mitochondrial function. In glaucomatous conditions, mitochondrial damage leads to the release of mitochondrial damage-associated molecular patterns (mtDAMPs), triggering chronic inflammation and tissue damage. This inflammation is exacerbated by the Senescence-Associated Secretory Phenotype (SASP), a process where senescent cells secrete bioactive molecules that contribute to cellular dysfunction and glaucoma progression.

Among potential neuroprotective approaches, nicotinamide (NAM) and its precursor nicotinamide riboside (NR) are gaining attention. These compounds support mitochondrial function and NAD production, which is essential for cellular vitality. Research indicates that reductions in NAM levels correlate with glaucoma progression. For instance, studies have shown that NAD precursors may prevent or delay RGC degeneration, suggesting a promising adjunctive treatment for glaucoma patients.

Study Objectives The study aims to measure NAM levels in ocular and non-ocular biological fluids (serum, aqueous humor, and tear fluid) of patients at different stages of glaucoma. The study will correlate NAM concentrations with disease severity and mitochondrial function markers. Furthermore, NAD levels in peripheral blood mononuclear cells (PBMCs) will be assessed to investigate potential biomarkers for glaucoma progression. A secondary objective is to evaluate the impact of dietary supplementation with nicotinamide and nicotinamide riboside (iNAD®) on NAD levels in pharmacologically controlled glaucoma patients.

Methods This cross-sectional, case-control, multi-center study involves three universities: University of G. d'Annunzio Chieti-Pescara, University of Pisa, and University of Sassari. Biological fluid analyses will be conducted at the Animal Biology Laboratory affiliated with the University of G. d'Annunzio Chieti-Pescara.

Patients will be categorized into four groups:

  1. Uncontrolled glaucoma patients scheduled for glaucoma surgery.
  2. Controlled glaucoma patients scheduled for cataract surgery.
  3. Healthy controls undergoing cataract surgery.
  4. Pharmacologically controlled glaucoma patients supplemented with iNAD®. Biological fluids (plasma, PBMCs, tear fluid, and aqueous humor) will be collected for analysis, including measures of NAD, mtDAMPs, and SASP components. These measures aim to provide insights into the molecular mechanisms underlying glaucoma and potential biomarkers for disease progression.

Statistical Analysis Sample size estimation was calculated using G*Power for a priori one-way ANOVA analysis. Assuming a mean NAM concentration of 0.14 μM (SD=0.12) for glaucoma patients and 0.19 μM (SD=0.13) for controls, with a power of 80% and alpha of 0.05, a minimum of 246 patients (82 per group) are required.

Read the detailed description

Background Glaucoma is a multifactorial, chronic, and progressive disease characterized by the irreversible loss of retinal ganglion cells (RGCs). It represents the second leading cause of blindness globally, but it is the leading cause of irreversible blindness, with 76 million patients affected worldwide in 2020. Unfortunately, it is estimated that the incidence of the disease will increase significantly in the next two decades, with approximately 120 million patients affected globally, particularly in Africa and Asia. Elevated intraocular pressure (IOP) is one of the most important risk factors for the development and progression of the disease, and its reduction is the only scientifically proven approach to controlling the decline in visual function. However, despite the reduction in IOP slowing the worsening of visual fields, many glaucoma patients continue to experience progressive loss of visual function despite IOP values within the statistical normal range. This is because glaucoma is a multifactorial disease, and simply reducing IOP does not guarantee the control of other risk factors damaging RGCs.

Among the mechanisms involved in the damage and death of RGCs in glaucoma, mitochondrial dysfunction appears to be one of the most important and earliest, leading the scientific literature to consider glaucoma, at least in part, as a particular form of mitochondrial disease. The need for direct neuroprotection, in addition to indirect neuroprotection (IOP reduction), represents a significant unmet need in the management of glaucoma patients. At present, despite numerous preclinical and some clinical evidence supporting the efficacy of certain molecules (such as citicoline) in protecting RGCs, there is no scientifically supported neuroprotective therapy in humans.

Two forms of vitamin B3, nicotinamide (NAM) and nicotinamide riboside (NR), are emerging as potential adjunctive therapies for the protection and enhancement of RGCs. These compounds are precursors to nicotinamide adenine dinucleotide (NAD). NAD is essential for the proper functioning of cells and is involved in various metabolic activities, including energy production, acting as a key cofactor in redox metabolism, including glycolysis, the citric acid cycle, oxidative phosphorylation, protection against reactive oxygen species, contributing to various enzymatic activities, and maintaining mitochondrial function.

Mitochondria, traditionally recognized for their role in bioenergy production and metabolite generation, are gaining increasing recognition for their various functions, including cellular signaling, cell death, regulation of reactive oxygen species (ROS), and inflammation. Given the high susceptibility of RGCs to mitochondrial damage, mitochondrial dysfunction becomes intricately linked to a series of cellular processes (aging, excitotoxicity, oxidative stress, mitophagy deficiency, prolonged inflammatory responses) associated with the pathogenesis of glaucoma. In glaucomatous conditions, the removal of defective mitochondria becomes crucial for maintaining mitochondrial quality control, thereby protecting cellular integrity. Consequently, mitochondrial dynamics, biogenesis, and mitophagy play crucial roles in ensuring effective mitochondrial quality control. Mitochondrial damage in neurons, particularly in RGCs, leads to the release of "Mitochondrial damage-associated molecular patterns" (mtDAMPs). These molecules act as triggers for chronic inflammation through pattern recognition receptors (PRRs) on glial cells and complementary activations in glaucoma. Numerous mtDAMPs, including mtDNA, ATP, cardiolipin, mitochondrial transcription factor A (TFAM), N-formyl peptides (NFPs), and cytochrome c, have been implicated in inducing an inflammatory process. The immunogenic nature of mtDNA, similar to bacterial DNA, activates interferon (IFN)-dependent genes, TLR9, the NLRP3 inflammasome, and the cGAS-STING signaling pathway. Defects in mitochondrial synthesis and maintenance, as well as alterations in mitophagy (autophagy of mitochondria), can contribute to dysfunctional accumulation, compromising energy (ATP) production and cellular metabolism regulation. These alterations can negatively impact cellular vitality and functionality, promoting cellular senescence. Emerging evidence suggests a link between glaucomatous conditions and cellular senescence. RGC senescence may contribute to the pathogenesis of glaucoma. The accumulation of senescent cells in the eye could lead to disrupted tissue homeostasis and compromised cellular function, potentially worsening glaucoma progression. Senescent cells can secrete a variety of bioactive molecules, a phenomenon known as Senescence-Associated Secretory Phenotype (SASP). SASP components released into bodily fluids include cytokines, chemokines, growth factors, and extracellular matrix remodeling enzymes. These factors can act in a paracrine manner, influencing nearby cells and contributing to chronic inflammation and tissue malfunction. In glaucoma, the presence of SASP components in biological fluids may indicate a dynamic interaction between senescent cells and the surrounding microenvironment. Understanding the presence and impact of senescence and SASP in biological fluids is crucial for unraveling the complex molecular mechanisms underlying glaucoma progression.

Emerging evidence has demonstrated that axonal degeneration in glaucomatous cells is associated with a decline in NAD, and the supplementation of NAD or NAD precursors (NAM or NR) may be effective in preventing or delaying RGC death in vitro and in vivo. In an experimental study, Williams and colleagues showed that oral administration of NAM was able to increase NAD levels in the retina and protect RGCs from degeneration in a murine glaucoma model. Interestingly, 93% of the experimental animals supplemented orally with a high dose of NAM (2000 mg/kg/day) did not develop RGC loss despite high IOP. Given its beneficial effects and evidence of reduced NAD bioavailability with aging, numerous research directions are exploring ways to restore cellular NAD pools in humans by administering its precursors.

Study Objectives Initial evidence has indicated a reduction in NAM concentrations by over 30% in the serum of glaucoma patients. However, no studies have been conducted to assess NAM levels in ocular biological fluids of patients with glaucoma at various stages of the disease.

The tear film, potentially rich in intraocular-derived molecules (due to trans-scleral flows of aqueous humor), and the aqueous humor itself, which directly bathes the sensitive sites of the disease (e.g., trabecular meshwork), are likely to express more significant and glaucoma-specific variations in NAM concentrations compared to those detectable in plasma or other distant fluids.

Studying ocular and non-ocular biological fluids can provide valuable insights into the molecular landscape associated with glaucoma. Analyzing these fluids for specific SASP markers, inflammatory cytokines, and molecules associated with mitochondrial dysfunction could reveal potential diagnostic and prognostic indicators for glaucoma progression.

Recent research has shown that in peripheral blood mononuclear cells (PBMC) from POAG patients, there is a reduction in mitochondrial respiration and NAD levels, and the degree of mitochondrial impairment correlates with the likelihood of glaucoma progression. In the same study, NAD levels in PBMC are proposed as a clinical diagnostic biomarker for glaucoma progression. Given various clinical studies investigating the effects of dietary supplementation with nicotinamide metabolic precursors on glaucoma progression, it is essential to demonstrate the impact of such treatments on NAD levels in PBMC among POAG patients.

Monitoring variations in senescence-associated molecules, alongside mitochondrial dysfunction linked to nicotinamide, could offer a non-invasive method to evaluate the severity and progression of the disease, enabling early interventions and personalized treatment strategies.

Main Outcomes:

  1. Measure NAM levels in serum, aqueous humor, and tear fluid in open-angle glaucoma (POAG): i) in patients with decompensated glaucoma candidates for glaucoma surgery; ii) in patients with pharmacologically controlled glaucoma candidates for cataract surgery; iii) and in healthy controls candidates for cataract surgery.
  2. Correlate NAM concentrations in the three fluids with disease stage, assessed through MD and VFI (Hodapp classification for staging) and RoP (if available).
  3. Correlate NAM levels with mitochondrial function indicators (mtDAMPs).
  4. Measure NAD content in PBMCs from the aforementioned patient cohorts.
  5. Measure NAD content in PBMCs from pharmacologically controlled POAG patients at baseline and after one month of dietary supplementation with a product containing nicotinamide and nicotinamide riboside (iNAD®).

Secondary Outcomes:

  1. Correlate NAM concentrations with pre-surgery IOP levels and baseline levels.
  2. Correlate NAD concentrations in aqueous humor with NAM levels in tear fluid and plasma.
  3. Assess if there is a different NAD concentration in primary and secondary (PEX/PG) open-angle glaucoma.
  4. Correlate NAD levels with SASP components. Methods Study Design This is a cross-sectional, case-control, multi-center study involving the University of G. d'Annunzio Chieti-Pescara (Prof. Luca Agnifili), the University of Pisa (Prof. Michele Figus), and the University of Sassari (Prof. Matteo Sacchi). The ophthalmology departments of the three universities will be responsible for patient enrollment, diagnostic and surgical procedures, and biological fluid sampling.

Biological fluid analyses will be conducted at the Animal Biology Laboratory (Body C, Level 1, Pharmacy Building) affiliated with the Biomorphology section of the Department of Medicine and Aging Sciences at the University of G. d'Annunzio Chieti-Pescara (Head: Prof. Antonia Patruno).

Patients

The study will recruit:

  • 90 patients with open-angle glaucoma (OAG) not pharmacologically controlled, receiving maximal tolerated medical therapy and scheduled for filtering glaucoma surgery (stand-alone or combined) (Group 1).
  • 90 patients with pharmacologically controlled OAG scheduled for cataract surgery (Group 2).
  • 90 healthy individuals scheduled for cataract surgery (Group 3).
  • 90 pharmacologically controlled OAG patients scheduled for cataract surgery and treated with iNAD (Group 4).

Before enrollment, each patient will sign an informed consent form outlining the nature and potential consequences of the study.

Procedures

  1. Ophthalmological Evaluation A complete ophthalmological evaluation will be conducted at enrollment, including best-corrected visual acuity, optical pachymetry using AS-OCT (CIRRUS HD-OCT 5000, ZEISS, Dublin, CA), Goldmann tonometry (three measurements between 8-10 am and 4 pm), gonioscopy, anterior and posterior segment analysis (in mydriasis) using slit lamp examination.
  2. Functional Stage Determination The glaucoma stage will be determined by measuring the mean defect (MD, dB) using standard automated perimetry (HFA; Carl Zeiss Meditec, Dublin, CA, USA) with the 24-2 SITA-Fast strategy. Defects will be classified according to Hodapp-Parrish-Anderson criteria: mild (MD > -6 dB), moderate (MD between -6 dB and -12 dB), advanced (MD \< -12 dB), and severe (MD \< -20 dB with central fixation loss). For patients with a sufficient number of visual fields performed on the same platform, a rate of progression will be calculated using trend analysis (GPA; HFA; Carl Zeiss Meditec, Dublin, CA, USA).
  3. OCT Imaging OCT measurements for average and sectoral RNFL and GCC thickness will be performed using the Cirrus platform.

Sampling of Biological Fluids Biological fluids will be collected simultaneously on the same day as the surgical procedure in the morning while fasting.

  1. Plasma and Peripheral Blood Mononuclear Cells (PBMCs) Isolation Blood samples will be collected in heparin tubes. Immediately after collection, tubes will be transported on ice to the Animal Biology Laboratory (Body C, Level 1, Pharmacy Building) at the University of G. d'Annunzio Chieti-Pescara (Head: Prof. Antonia Patruno), where PBMC isolation and plasma recovery will be performed.

    For participants at the two off-site ophthalmology units, blood samples will be collected in heparin tubes and treated with an appropriate volume of TransFix® (200 µL TransFix® per 1000 µL of blood, 1:5 ratio). Blood treated with TransFix® may be stored for up to 14 days at 2-8°C, suitable for transfer to the Animal Biology Laboratory at the University of G. d'Annunzio Chieti-Pescara.

    PBMCs will be separated from other components by centrifugation for 30 minutes at 1500 rpm using a density gradient with Ficoll-Paque (density: 1.007 g/mL). Red blood cells, granulocytes, and dead cells will pass through the Ficoll layer, while lymphocytes and monocytes will accumulate at the plasma-Ficoll interface forming a cell ring. The plasma will be collected in a 1:1 ratio with PBS and gently mixed with Ficoll in a 1:1 ratio. Following centrifugation at 1500 rpm for 30 minutes at 22°C, plasma will be collected and stored at -80°C.

    The PBMC cell ring will be washed twice with PBS to remove the supernatant and resuspended in QIAzol (lysis reagent, QIAGEN Sciences, MD, USA) for RNA isolation, then frozen at -80°C.

  2. Tear Film Tear samples will be obtained using a Schirmer strip inserted into the inferior conjunctival sac for 5 minutes with eyes closed. Each Schirmer strip will be placed in an Eppendorf tube and transported on ice to the Animal Biology Laboratory (Body C, Level 1, Pharmacy Building) at the University of G. d'Annunzio Chieti-Pescara (Head: Prof. Antonia Patruno), where the tear film recovery protocol will be performed.

    For off-site ophthalmology units, tear samples will be stored at -20°C and transferred on dry ice to the Animal Biology Laboratory.

    Tear film recovery: Each Schirmer strip soaked with tears will be placed in 70 µL of T-PER (Tissue Protein Extraction Reagent, Pierce) at room temperature for 2 hours. The Schirmer strip will then be collected and centrifuged at 4°C at 13,000 g for 2 minutes. The tear solution (80±5µL, 1.5±0.5µg µL-1) will be divided into aliquots and stored at -80°C.

  3. Aqueous Humor Aqueous humor (0.5 - 1 ml) will be collected immediately and carefully at the beginning of surgery, prior to any surgical steps, via anterior chamber paracentesis using a 27-gauge needle connected to a tuberculin syringe under a surgical microscope. During this procedure, intraocular tissues such as the iris and lens will be carefully avoided. The aqueous humor will be immediately transferred to the Animal Biology Laboratory (Body C, Level 1, Pharmacy Building) at the University of G. d'Annunzio Chieti-Pescara (Head: Prof. Antonia Patruno) and stored at -80°C until all tests are performed. All samples will be protected from light.

    For off-site units, samples will be stored at -20°C and transferred on dry ice to the Animal Biology Laboratory.

  4. NAD Quantification Total NAD (NAD and NADH) will be quantified using a spectrophotometric assay with a reference wavelength of 450 nm.
  5. mtDAMPS Analysis

    1. Extraction of nucleic acids: Isolation of mtDNA from biological samples.
    2. ATP levels will be measured using luminometric techniques.
    3. Cardiolipin levels will be assessed using chromatography techniques.
    4. TFAM levels will be evaluated through immunoprecipitation techniques.
    5. Detection of formylated peptides (NFPs) using mass spectrometry.
    6. Cytochrome c levels will be measured via immuno-enzymatic techniques.
  6. SASP Measurement Quantitative analysis of specific SASP components (e.g., IL-6, IL-8, MMPs, PAI-1) will be performed using immuno-enzymatic techniques (ELISA). Results validation will be done via Western blot to identify specific SASP proteins.

Statistical Analysis.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • Nicotinamide
  • mtDAMPs
  • SASP
  • aqueous humor
  • tear film
  • senescence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Group 1 Inclusion Criteria

  • Age > 18 years
  • Diagnosis of open-angle glaucoma (primary open-angle glaucoma)
  • Uncontrolled IOP (> 21 mmHg as the mean of three measurements between 8-10 am and 16),
  • Maximal medical therapy
  • Perimetric-OCT and ophthalmic optic neuropathy criteria
  • Indication for standalone or combined glaucoma surgery (any surgery allowing aqueous humor sampling: MIGS, MIBS, TRABE, DS, canal surgery, drainage tube implants, revision of surgical implant)

Group 2 and 4 Inclusion Criteria

  • Age > 18 years
  • Diagnosis of open-angle glaucoma
  • Controlled IOP (≤ 21 mmHg as the mean of three measurements between 8-10 am and 16) under medical therapy (excluding oral acetazolamide)
  • Perimetric-OCT and ophthalmic optic neuropathy criteria.

Group 3 Inclusion Criteria:

  • Age >18 years
  • IOP ≤ 21 mmHg
  • Absence of perimetric-OCT and ophthalmic optic neuropathy criteria for glaucoma.

Exclusion Criteria for all groups

  • Conditions and systemic therapies influencing NAM levels in biological fluids
  • Concomitant ocular pathologies beyond glaucoma or cataracts
  • Ocular therapies beyond hypotensive eye drops
  • Prior ocular surgeries
  • Secondary glaucomas (uveitic, silicone oil, traumatic, neovascular)
  • End-stage glaucoma or severe glaucoma (\<-20 dB)
  • Pregnancy and breastfeeding.
  • (only for Group 3) family history of glaucoma and transient IOP spikes
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • No intervention
    OAG not pharmacologically controlled, receiving MTM and scheduled for filtering glaucoma surgery

    Patients with open-angle glaucoma (OAG) not pharmacologically controlled, receiving maximal tolerated medical therapy and scheduled for filtering glaucoma surgery (stand-alone or combined). To this arm will be administered ophthalmological evaluation, functional stage determination, OCT imaging, sampling and analysis of biological fluids (Plasma and Peripheral Blood Mononuclear Cells (PBMCs) Isolation, Tear Film, Aqueous Humor; NAD Quantification in all biological fluids, mtDAMPS and SASP quantification in PBMCs)

  • No intervention
    Pharmacologically controlled OAG scheduled for cataract surgery

    Patients with pharmacologically controlled OAG scheduled for cataract surgery. To this arm will be administered ophthalmological evaluation, functional stage determination, OCT imaging, sampling and analysis of biological fluids (Plasma and Peripheral Blood Mononuclear Cells (PBMCs) Isolation, Tear Film, Aqueous Humor; NAD Quantification in all biological fluids, mtDAMPS and SASP quantification in PBMCs)

  • No intervention
    Healthy individuals scheduled for cataract surgery

    Healthy individuals scheduled for cataract surgery. To this arm will be administered ophthalmological evaluation, functional stage determination, OCT imaging, sampling and analysis of biological fluids (Plasma and Peripheral Blood Mononuclear Cells (PBMCs) Isolation, Tear Film, Aqueous Humor; NAD Quantification in all biological fluids, mtDAMPS and SASP quantification in PBMCs)

  • Experimental
    Pharmacologically controlled OAG patients scheduled for cataract surgery and treated with iNAD

    Pharmacologically controlled OAG patients scheduled for cataract surgery and treated with iNAD. To this arm will be administered iNAD during the month preceding surgery and ophthalmological evaluation, functional stage determination, OCT imaging, sampling and analysis of biological fluids (Plasma and Peripheral Blood Mononuclear Cells (PBMCs) Isolation, Tear Film, Aqueous Humor; NAD Quantification in all biological fluids, mtDAMPS and SASP quantification in PBMCs)

    Dietary Supplement: Nicotinamide Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Nicotinamide levels measurement in biologic fluids

    Measure nicotinamide levels in serum, aqueous humor, and tear fluid in open-angle glaucoma (POAG): i) in patients with decompensated glaucoma candidates for glaucoma surgery; ii) in patients with pharmacologically controlled glaucoma candidates for cataract surgery; iii) and in healthy controls candidates for cataract surgery.

    Time frame: Day 1

  2. Nicotinamide levels clinical correlation

    Correlate NAM concentrations in the three fluids with disease stage, assessed through MD and VFI (Hodapp classification for staging) and RoP (if available).

    Time frame: Day 1

  3. Nicotinamide levels - mtDAMPs correlation

    Correlate NAM levels with mitochondrial function indicators (mtDAMPs).

    Time frame: Day 1

  4. Nicotinamide levels measurement in PBMCs

    Measure NAD content in PBMCs

    Time frame: Day 1

  5. Nicotinamide levels measurement after dietary supplementation

    Measure NAD content in PBMCs from pharmacologically controlled POAG patients at baseline and after 4 weeks of dietary supplementation with a product containing nicotinamide riboside

    Time frame: At enrollment and at the end of treatment at 4 weeks

Secondary outcomes

  1. Nicotinamide levels - IOP correlation

    Correlate NAM concentrations with pre-surgery IOP levels and baseline levels.

    Time frame: Day 1

  2. Nicotinamide levels in different biological fluids correlation

    Correlate NAD concentrations in aqueous humor with NAM levels in tear fluid and plasma

    Time frame: Day 1

  3. Nicotinamide levels in different OAG types

    Assess if there is a different NAD concentration in primary and secondary (PEX/PG) open-angle glaucoma

    Time frame: Day 1

  4. Nicotinamide levels - SASP correlation

    Correlate NAD levels with SASP components

    Time frame: Day 1

07

Study locations

3 sites
  • Clinica Oftalmologica - Ospedale Clinicizzato SS Annunziata di Chieti
    Chieti Scalo, Chieti 66100, Italy
  • U.O. Oculistica Universitaria
    Pisa, 56124, Italy
  • Clinica Oculistica AOU Sassari
    Sassari, 07100, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Dec 2026, 14 months later.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 14 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Jun 5, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07006194
Lead sponsor
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Collaborators
OFFHEALTH S.p.A., Università degli Studi di Sassari, University of Pisa
Responsible party
Luca Agnifili (Associate Professor, Università degli Studi 'G. d'Annunzio' Chieti e Pescara) — Principal investigator
First posted
Jun 5, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 5, 2025

Study contacts

Luca Agnifili, Principal Investigator
Contact
l.agnifili@unich.it
+390871357219

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niacinamide

Start the discussion